Fiduciary Planning LLC Has $455,000 Stake in Eli Lilly and Company $LLY

Fiduciary Planning LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 12.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 584 shares of the company’s stock after acquiring an additional 65 shares during the quarter. Fiduciary Planning LLC’s holdings in Eli Lilly and Company were worth $455,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Princeton Global Asset Management LLC grew its holdings in Eli Lilly and Company by 26.6% in the second quarter. Princeton Global Asset Management LLC now owns 585 shares of the company’s stock worth $456,000 after purchasing an additional 123 shares during the period. Schnieders Capital Management LLC boosted its position in shares of Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. FLC Capital Advisors grew its stake in shares of Eli Lilly and Company by 8.9% in the 2nd quarter. FLC Capital Advisors now owns 1,111 shares of the company’s stock valued at $866,000 after buying an additional 91 shares during the period. Stephens Inc. AR increased its position in Eli Lilly and Company by 3.6% in the 2nd quarter. Stephens Inc. AR now owns 37,781 shares of the company’s stock valued at $29,452,000 after buying an additional 1,296 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc. raised its stake in Eli Lilly and Company by 19.6% during the 2nd quarter. Mountain Capital Investment Advisors Inc. now owns 531 shares of the company’s stock worth $412,000 after buying an additional 87 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 1.9%

Shares of LLY stock opened at $803.53 on Monday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $760.51 billion, a price-to-earnings ratio of 52.52, a PEG ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a 50-day simple moving average of $753.09 and a two-hundred day simple moving average of $765.70.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. HSBC raised their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a report on Sunday, August 17th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $939.12.

Insider Transactions at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.